期刊
HUMAN VACCINES & IMMUNOTHERAPEUTICS
卷 17, 期 9, 页码 2841-2850出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/21645515.2021.1920271
关键词
COVID-19; mortality; propensity score; case-control; statins; ACE inhibitors; angiotensin receptor blockers; immunometabolism
The COVID-19 pandemic has drastically impacted the world, but observational studies suggest that treating COVID-19 patients with statins and ACEI/ARB medications could reduce mortality rates. Combined treatment with these drugs may further decrease in-hospital mortality rates.
The COVID-19 pandemic has disrupted life throughout the world. Newly developed vaccines promise relief to people who live in high-income countries, although vaccines and expensive new treatments are unlikely to arrive in time to help people who live in low-and middle-income countries. The pathogenesis of COVID-19 is characterized by endothelial dysfunction. Several widely available drugs like statins, ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have immunometabolic activities that (among other things) maintain or restore endothelial cell function. For this reason, we undertook an observational study in four Belgian hospitals to determine whether in-hospital treatment with these drugs could improve survival in 959 COVID-19 patients. We found that treatment with statins and ACEIs/ARBs reduced 28-day mortality in hospitalized COVID-19 patients. Moreover, combination treatment with these drugs resulted in a 3-fold reduction in the odds of hospital mortality (OR = 0.33; 95% CI 0.17-0.69). These findings were in general agreement with other published studies. Additional observational studies and clinical trials are needed to convincingly show that in-hospital treatment with statins, ACEIs/ARBs, and especially their combination saves lives.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据